Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
The T1D Fund is a not-for-profit organization dedicated to accelerating treatments, prevention, and cures for Type 1 Diabetes (T1D). Founded as a wholly owned subsidiary of Breakthrough T1D, the organization operates from Boston, Massachusetts. With over $200 million in assets under management, the T1D Fund actively manages a portfolio of more than 25 companies. The fund leverages its expertise in investment banking, pharmaceuticals, and business development to catalyze innovation in T1D therapies. The T1D Fund is recognized for its commitment to fostering advancements in healthcare, particularly in the realm of chronic diseases, and is well-regarded within the biotech community for its strategic investments and support of groundbreaking research.
The T1D Fund invests in companies that are developing disease-modifying therapies and cures for Type 1 Diabetes. Its investment strategy is modality agnostic, targeting a wide range of therapeutic approaches, including autoimmune and regeneration, cell replacement, and metabolic control. The fund seeks to support differentiated, curative potential treatments across various stages of development, from discovery to clinical assets. This flexibility allows the T1D Fund to engage with innovative companies at different points in their growth trajectory, from pre-seed to Series C funding. Geographically, the T1D Fund's investments span the globe, reflecting a belief that innovation knows no boundaries. The organization is particularly interested in supporting companies that demonstrate a strong potential for transformative impact in the T1D space.
The T1D Fund's portfolio includes notable companies that are at the forefront of developing innovative solutions for Type 1 Diabetes. Among its investments are AnTolRx, Inc., which is developing antigen-specific immune tolerance therapies; AltruBio, targeting T cell mediated autoimmune diseases; and Bigfoot Biomedical, which is creating a comprehensive diabetes management ecosystem. Other significant portfolio companies include Biolinq, known for its biosensor patch technology; Capillary Biomedical, innovating insulin infusion set technology; and COUR Pharmaceuticals, which delivers disease-specific antigens. Additionally, Diasome Pharmaceuticals focuses on liver-targeted insulin, while eGenesis Bio works on renewable islet sources. Kriya Therapeutics utilizes gene therapy for insulin independence, and ImmusanT is developing peptide desensitization therapy. This diverse portfolio underscores the T1D Fund's commitment to supporting a wide array of therapeutic innovations aimed at improving the lives of those affected by T1D.
To pitch the T1D Fund, founders should visit their official website at t1dfund.org to submit their proposals. The fund is open to various formats but emphasizes the importance of clearly articulating the innovative aspects of the therapy and its potential impact on Type 1 Diabetes.
The T1D Fund invests across multiple stages, including Pre Seed, Seed, Seed Plus, Series A, Series B, and Series C. This broad range allows them to support companies at various points in their development journey.
Founders interested in pitching to the T1D Fund can submit their proposals through their official website at t1dfund.org. It is advisable to provide a clear overview of the company's mission, the innovative aspects of the therapy being developed, and how it addresses the challenges of Type 1 Diabetes.
The T1D Fund primarily focuses on the healthcare and biotech sectors, specifically targeting companies that are developing disease-modifying therapies and cures for Type 1 Diabetes. Their investment strategy is modality agnostic, allowing for a diverse range of therapeutic approaches.
While specific check sizes are not disclosed, the T1D Fund invests across various stages, indicating flexibility in funding amounts depending on the needs of the company and the stage of development.
The T1D Fund invests globally, reflecting its belief that innovation knows no boundaries. This global approach allows them to support a wide range of therapeutic innovations from various regions.
Founders can apply for funding by submitting their proposals through the T1D Fund's website. It is recommended to include detailed information about the company's technology, market potential, and how it aligns with the fund's mission to accelerate T1D therapies.
The T1D Fund leverages its expertise in investment banking, pharmaceuticals, and business development to support its portfolio companies. This includes strategic guidance, networking opportunities, and access to resources that can help accelerate the development of innovative therapies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.